https://orcid.org/0000-0002-6593-0140
Key Points
Time-limited acalabrutinib, venetoclax, and obinutuzumab induced deep and ongoing remission in patients with relapsed/refractory CLL.
The addition of ctDNA-based analyses to conventional FCM appears to improve early detection of molecular and clinical relapses.
Abstract
The phase 2 CLL2-BAAG trial tested the measurable residual disease (MRD)–guided triple combination of acalabrutinib, venetoclax, and obinutuzumab after optional bendamustine debulking in 45 patients with relapsed/refractory chronic lymphocytic leukemia (CLL). MRD was measured by flow cytometry (FCM; undetectable MRD <10–4) in peripheral blood (PB) and circulating tumor DNA (ctDNA) using digital droplet polymerase chain reaction of variable-diversity-joining (VDJ) rearrangements and CLL-related mutations in plasma. The median number of previous treatments was 1 (range, 1-4); 18 patients (40%) had received a Bruton tyrosine kinase inhibitor (BTKi) and/or venetoclax before inclusion, 14 of 44 (31.8%) had TP53 aberrations, and 34 (75.6%) had unmutated immunoglobulin heavy-chain variable region genes. With a median observation time of 36.3 months and all patients off-treatment for a median of 21.9 months, uMRD <10–4 in PB was achieved in 42 of the 45 patients (93.3%) at any time point, including 17 of 18 (94.4%) previously exposed to venetoclax/BTKi and 13 of 14 (92.9%) with TP53 aberrations. The estimated 3-year progression-free and overall survival rates were 85.0% and 93.8%, respectively. Overall, 585 paired FCM/ctDNA samples were analyzed and 18 MRD recurrences (5 with and 13 without clinical progression) occurred after the end of treatment. Twelve samples were first detected by ctDNA, 3 by FCM, and 3 synchronously. In conclusion, time-limited MRD-guided acalabrutinib, venetoclax, and obinutuzumab achieved deep remissions in almost all patients with relapsed/refractory CLL. The addition of ctDNA-based analyses to FCM MRD assessment seems to improve early detection of relapses. This trial was registered at www.clinicaltrials.gov as #NCT03787264.
References
1.
Hallek
M
, Al-Sawaf
O
. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
. Am J Hematol
. 2021
;96
(12
):1679
-1705
.2.
Eichhorst
B
, Niemann
CU
, Kater
AP
, et al. First-line venetoclax combinations in chronic lymphocytic leukemia
. N Engl J Med
. 2023
;388
(19
):1739
-1754
.3.
Fischer
K
, Al-Sawaf
O
, Bahlo
J
, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions
. N Engl J Med
. 2019
;380
(23
):2225
-2236
.4.
Burger
JA
, Tedeschi
A
, Barr
PM
, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
. N Engl J Med
. 2015
;373
(25
):2425
-2437
.5.
Byrd
JC
, Furman
RR
, Coutre
SE
, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
. N Engl J Med
. 2013
;369
(1
):32
-42
.6.
Jain
N
, Keating
M
, Thompson
P
, et al. Ibrutinib and venetoclax for first-line treatment of CLL
. N Engl J Med
. 2019
;380
(22
):2095
-2103
.7.
Sharman
JP
, Egyed
M
, Jurczak
W
, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial
. Lancet
. 2020
;395
(10232
):1278
-1291
.8.
Woyach
JA
, Ruppert
AS
, Heerema
NA
, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL
. N Engl J Med
. 2018
;379
(26
):2517
-2528
.9.
Kater
AP
, Owen
C
, Moreno
C
, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities
. NEJM Evid
. 2022
;1
(7
):EVIDoa2200006
.10.
Stilgenbauer
S
, Eichhorst
B
, Schetelig
J
, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial
. J Clin Oncol
. 2018
;36
(19
):1973
-1980
.11.
Seymour
JF
, Kipps
TJ
, Eichhorst
B
, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia
. N Engl J Med
. 2018
;378
(12
):1107
-1120
.12.
Brown
JR
, Eichhorst
B
, Hillmen
P
, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia
. N Engl J Med
. 2023
;388
(4
):319
-332
.13.
Wierda
WG
, Allan
JN
, Siddiqi
T
, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study
. J Clin Oncol
. 2021
;39
(34
):3853
-3865
.14.
Mato
AR
, Woyach
JA
, Brown
JR
, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia
. N Engl J Med
. 2023
;389
(1
):33
-44
.15.
Cramer
P
, von Tresckow
J
, Bahlo
J
, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
. Lancet Oncol
. 2018
;19
(9
):1215
-1228
.16.
Rogers
KA
, Huang
Y
, Ruppert
AS
, et al. Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naïve and relapsed or refractory chronic lymphocytic leukemia
. J Clin Oncol
. 2020
;38
(31
):3626
-3637
.17.
Davids
MS
, Lampson
BL
, Tyekucheva
S
, et al. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study
. Lancet Oncol
. 2021
;22
(10
):1391
-1402
.18.
Cramer
P
, Fürstenau
M
, Robrecht
S
, et al. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial
. Lancet Haematol
. 2022
;9
(10
):e745
-e755
.19.
Soumerai
JD
, Mato
AR
, Dogan
A
, et al. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
. Lancet Haematol
. 2021
;8
(12
):e879
-e890
.20.
Huber
H
, Edenhofer
S
, von Tresckow
J
, et al. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia
. Blood
. 2022
;139
(9
):1318
-1329
.21.
Ryan
CE
, Lampson
BL
, Tyekucheva
S
, et al. Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease [abstract]
. Blood
. 2022
;140
(suppl 1
):837
-838
.22.
Huber
H
, Tausch
E
, Schneider
C
, et al. Final analysis of the CLL2-GIVe trial (obinutuzumab, ibrutinib, and venetoclax) in untreated CLL with del(17p)/TP53mut
. Blood
. 2023
;142
(11
):961
-972
.23.
Alig
S
, Macaulay
CW
, Kurtz
DM
, et al. Short diagnosis-to-treatment interval is associated with higher circulating tumor DNA levels in diffuse large B-cell lymphoma
. J Clin Oncol
. 2021
;39
(23
):2605
-2616
.24.
Kurtz
DM
, Scherer
F
, Jin
MC
, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma
. J Clin Oncol
. 2018
;36
(28
):2845
-2853
.25.
Kurtz
DM
, Soo
J
, Co Ting Keh
L
, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
. Nat Biotechnol
. 2021
;39
(12
):1537
-1547
.26.
Mutter
JA
, Alig
SK
, Esfahani
MS
, et al. Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas
. J Clin Oncol
. 2023
;41
(9
):1684
-1694
.27.
Spina
V
, Bruscaggin
A
, Cuccaro
A
, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
. Blood
. 2018
;131
(22
):2413
-2425
.28.
Sobesky
S
, Mammadova
L
, Cirillo
M
, et al. In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection
. Med
. 2021
;2
(10
):1171
-1193.e11
.29.
Fürstenau
M
, Weiss
J
, Giza
A
, et al. Circulating tumor DNA-Based MRD assessment in patients with CLL treated with obinutuzumab, acalabrutinib, and venetoclax
. Clin Cancer Res
. 2022
;28
(19
):4203
-4211
.30.
Huggett
JF
; dMIQE Group
. The digital MIQE guidelines update: minimum information for publication of quantitative digital PCR experiments for 2020
. Clin Chem
. 2020
;66
(8
):1012
-1029
.31.
Rawstron
AC
, Villamor
N
, Ritgen
M
, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
. Leukemia
. 2007
;21
(5
):956
-964
.32.
Hallek
M
, Cheson
BD
, Catovsky
D
, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
. Blood
. 2018
;131
(25
):2745
-2760
.33.
Quinquenel
A
, Fornecker
LM
, Letestu
R
, et al. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study
. Blood
. 2019
;134
(7
):641
-644
.34.
Woyach
J
, Huang
Y
, Rogers
K
, et al. Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations [abstract]
. Blood
. 2019
;134
(suppl 1
):504
.35.
Woyach
JA
, Ruppert
AS
, Guinn
D
, et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia
. J Clin Oncol
. 2017
;35
(13
):1437
-1443
.36.
Blombery
P
, Anderson
MA
, Gong
JN
, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
. Cancer Discov
. 2019
;9
(3
):342
-353
.37.
Blombery
P
, Thompson
ER
, Nguyen
T
, et al. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
. Blood
. 2020
;135
(10
):773
-777
.38.
Lew
TE
, Lin
VS
, Cliff
ER
, et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
. Blood Adv
. 2021
;5
(20
):4054
-4058
.39.
Thijssen
R
, Tian
L
, Anderson
MA
, et al. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
. Blood
. 2022
;140
(20
):2127
-2141
.40.
Kater
AP
, Wu
JQ
, Kipps
T
, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study
. J Clin Oncol
. 2020
;38
(34
):4042
-4054
.41.
Kater
AP
, Seymour
JF
, Hillmen
P
, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study
. J Clin Oncol
. 2019
;37
(4
):269
-277
.42.
Byrd
JC
, Hillmen
P
, Ghia
P
, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial
. J Clin Oncol
. 2021
;39
(31
):3441
-3452
.43.
Al-Sawaf
O
, Zhang
C
, Lu
T
, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study
. J Clin Oncol
. 2021
;39
(36
):4049
-4060
.44.
Blombery
P
, Thompson
ER
, Lew
TE
, et al. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
. Blood Adv
. 2022
;6
(20
):5589
-5592
.45.
Estupiñán
HY
, Wang
Q
, Berglöf
A
, et al. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
. Leukemia
. 2021
;35
(5
):1317
-1329
.46.
Wang
E
, Mi
X
, Thompson
MC
, et al. Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors
. N Engl J Med
. 2022
;386
(8
):735
-743
.47.
Qi
J
, Endres
S
, Yosifov
DY
, et al. Acquired BTK mutations associated with resistance to non-covalent BTK inhibitors
. Blood Adv
. 2023
;7
(19
):5698
-5702
.48.
Thompson
MC
, Harrup
RA
, Coombs
CC
, et al. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
. Blood Adv
. 2022
;6
(15
):4553
-4557
.49.
Lew
TE
, Tam
CS
, Seymour
JF
. How I treat chronic lymphocytic leukemia after venetoclax
. Blood
. 2021
;138
(5
):361
-369
.50.
Mato
AR
, Thompson
M
, Allan
JN
, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
. Haematologica
. 2018
;103
(9
):1511
-1517
.51.
Yeh
P
, Hunter
T
, Sinha
D
, et al. Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia
. Nat Commun
. 2017
;8
:14756
.52.
Hengeveld
PJ
, van der Klift
MY
, Kolijn
PM
, et al. Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL
. Blood
. 2023
;141
(5
):519
-528
.53.
Fürstenau
M
, Schilhabel
A
, Robrecht
S
, et al. High resolution assessment of minimal residual disease (MRD) by next-generation sequencing (NGS) and high-sensitivity flow cytometry (hsFCM) in the phase 3 GAIA (CLL13) trial [abstract]
. Blood
. 2021
;138
(suppl 1
):72
.54.
Munir
T
, Moreno
C
, Owen
C
, et al. Impact of minimal residual disease on progression-free survival outcomes after fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in the GLOW study
. J Clin Oncol
. 2023
;41
(21
):3689
-3699
.55.
Thompson
PA
, Srivastava
J
, Peterson
C
, et al. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy
. Blood
. 2019
;134
(22
):1951
-1959
.© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2024
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal